Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eprosartan/HCTZ vs Ramipril/HCTZ plus moxonidine in hypertensive patients with type 2 diabetes mellitus
2004-000703-18Phase 3Active
- Sponsor
- Solvay
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension and type 2 diabetes mellitus (T2DM) comparing Eprosartan/HCTZ + moxonidine with Ramipril/HCTZ + moxonidine (2 arms). Primary endpoint: Blood pressure goal achievement at 4 weeks. Started Mar 2005; status: active.
02
Drugs
eprosartanramiprilmoxonidinehydrochlorothiazide
03
Conditions
essential hypertensiontype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-000703-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000703-18.